Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial)

Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial)

Abstract Background For complete revascularization, patients with diffuse coronary artery disease should have a coronary endarterectomy and a coronary artery bypass graft (CE-CABG). Sadly, CE can lead to a lack of endothelium, which raises the risk of thrombotic events. Even though daily dual antipl...

Full description

Bibliographic Details
Main Authors: Liang Chen, Ming-Xin Gao, Xin Du, Chi Wang, Wen-Yuan Yu, Hong-Li Liu, Xiao-Hang Ding, Bo-Lin Wang, Kui Zhang, Dong Xu, Zhen Han, Bao-Dong Xie, Ran Dong, Yang Yu
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Trials
Subjects:
Tirofiban
Heparin
Coronary endarterectomy
Coronary artery bypass grafting
Antithrombotic therapy
Major cardiovascular and cerebrovascular events
Online Access:https://doi.org/10.1186/s13063-023-07737-8

Internet

https://doi.org/10.1186/s13063-023-07737-8

Similar Items